These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 8960843

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
    Bijlstra PJ, Lutterman JA, Russel FG, Thien T, Smits P.
    Diabetologia; 1996 Sep; 39(9):1083-90. PubMed ID: 8877293
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans.
    de Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM.
    Clin Pharmacol Ther; 2003 Apr; 73(4):312-21. PubMed ID: 12709721
    [Abstract] [Full Text] [Related]

  • 7. Blockade of adenosine triphosphate-sensitive potassium channels eliminates isoflurane-induced coronary artery vasodilation.
    Cason BA, Shubayev I, Hickey RF.
    Anesthesiology; 1994 Nov; 81(5):1245-55; discussion 27A-28A. PubMed ID: 7978484
    [Abstract] [Full Text] [Related]

  • 8. Microcirculatory effects of KATP channel blockade by sulphonylurea derivatives in humans.
    Abbink EJ, Wollersheim H, Netten PM, Russel FG, Lutterman JA, Smits P.
    Eur J Clin Invest; 2002 Mar; 32(3):163-71. PubMed ID: 11895467
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Wascher TC, Boes U.
    Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
    Abbink EJ, Pickkers P, van Rosendaal AJ, Lutterman JA, Tack CJ, Russel FG, Smits P.
    Clin Sci (Lond); 2002 Mar; 102(3):307-14. PubMed ID: 11869171
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
    Mortensen UM, Nielsen-Kudsk JE, Sondergaard HM, Jakobsen P, Jensen BS, Schmitz O, Nielsen TT.
    Diabet Med; 2006 Mar; 23(3):327-30. PubMed ID: 16492219
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.